Clinical trials: Liver Disease
Hepatitis C
Safety and Pharmacokinetics of MK-7680 in Participants With Hepatitis C (MK-7680-003)
This is a two-part dose-finding trial of MK-7680 in participants with Hepatitis C Virus (HCV) infection of genotype (GT)1 (Part I) and GT3 (Part 2).
- Trial name
- NCT02269059
- Testing
- MK-7680
- Volunteers
- 13 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants
The purpose of this study was to evaluate the safety, tolerability, and efficacy of 12 weeks of treatment with sovaprevir, ACH-0143102, and ribavirin (RBV) in genotype-1 (GT-1), treatment-naive, hepatitis C virus (HCV)…
- Trial name
- NCT01849562
- Testing
- Sovaprevir, ACH-3102, Ribavirin
- Volunteers
- 30 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hepatitis B
A Study to Compare Blood Levels of Bepirovirsen and Safety Using Different Methods of Injecting in Healthy Adult Participants
This is an open-label study being done to compare two different methods of study medicine bepirovirsen is given in healthy adults.
- Trial name
- NCT07905157
- Testing
- Bepirovirsen
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B, Chronic, Hepatitis D, Chronic
A Long Term Follow-up Study of Patients From the REP 301 Protocol
The REP 301 treatment protocol involved the treatment of patients with chronic hepatitis B / hepatitis D co-infection with two agents: REP 2139-Ca and pegylated interferon (peg-IFN).
- Trial name
- NCT02876419
- Where
- Moldova
- Volunteers
- 11 people
- Sponsor
- Replicor Inc.
Hepatitis B
Persistence of the Immune Response to Hepatitis B in 7-9 Years Old Children Previously Vaccinated With DTPa-HBV-IPV/Hib
Persistence of seroprotective antibody concentrations \& immunological memory shown by the ability to mount a response to a challenge dose of HBV vaccine
- Trial name
- NCT00356564
- Testing
- hepatitis B vaccine
- Where
- 42 sites in Germany
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C Virus
Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in India
This study will evaluate the safety and efficacy of sofosbuvir (SOF)-based regimens administered as per the approved prescribing information in adults with chronic hepatitis C virus (HCV) infection treated in routine clinical…
- Trial name
- NCT02592057
- Testing
- SOF
- Where
- 26 sites in India
- Volunteers
- 532 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)
This is a randomized, open-label, multinational study designed to evaluate the "standard" regimen, PegIntron 1.5 µg/kg subcutaneously once weekly plus ribavirin 800-1200 mg daily [Arm PEG2b 1.5/R (24 weeks)], compared to a lower…
- Trial name
- NCT00302081
- Testing
- peginterferon alfa-2b (SCH 54031), ribavirin (SCH 18908)
- Volunteers
- 696 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Hepatocellular Carcinoma
Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
The primary objective is to determine if the administration of a combination of sofosbuvir (SOF; GS-7977; PSI-7977) and ribavirin (RBV) to HCV-infected adults with hepatocellular carcinoma (HCC) meeting the MILAN criteria prior…
- Trial name
- NCT01559844
- Testing
- Sofosbuvir, Ribavirin
- Where
- 15 sites in United States, New Zealand and 1 more
- Volunteers
- 61 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection.
The purpose of this study is to determine whether a 10-day course of therapy with orally administered VCH-759 given at 400-mg, 600-mg or 800-mg three times daily can effectively reduce the amount of circulating virus (i.e., viral…
- Trial name
- NCT00389298
- Testing
- VCH-759 (BCH-27759)
- Where
- 4 sites in Canada
- Volunteers
- 36 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatitis C
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
The purpose of this research study is to find out the effect of the investigational drug NOV-205 on the level of hepatitis C virus in the blood and whether NOV-205 is well-tolerated at different doses when taken by subjects with…
- Trial name
- NOV-205 (NCT01058512)
- Testing
- NOV-205
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Cellectar Biosciences, Inc.
Hepatitis B, Chronic
Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects
Bile acids regulating farnesoid X receptor (FXR) interact with hepatitis B virus replication. EYP001a is a selective, synthetic FXR agonist under development for the treatment of hepatitis B.
- Trial name
- NCT03272009
- Testing
- EYP001a, Entecavir, peg-interferon alfa-2a
- Where
- 9 sites in Australia, Netherlands and 2 more
- Volunteers
- 73 people
- Sponsor
- Enyo Pharma
Hepatitis C Virus Infection
Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) administered for 12 or 24 weeks in adults with genotype 1 or 4…
- Trial name
- NCT02301936
- Testing
- LDV/SOF
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Gilead Sciences
HCV Infection
Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir
The purpose of this study is to evaluate the effect of food on pharmacokinetics, safety and tolerability of an experimental Hepatitis C Virus (HCV) protease inhibitor with ritonavir in healthy volunteers.
- Trial name
- NCT00909311
- Testing
- ABT-450, ritonavir
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Abbott
Cancer, Neoplasms
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
- Conditions
- Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04260802
- Testing
- OC-001, Drug: OC-001 in Combination with Avelumab
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Ocellaris Pharma, Inc.
Hepatitis C, Chronic
Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV
The purpose of the study was to assess in subjects with chronic hepatitis C (treatment-naïve, genotype 1) receiving weight-based doses of ribavirin the virologic response to 3 dose levels of Locteron™, dosed every 2 weeks, in…
- Trial name
- SELECT-2 (NCT00863239)
- Testing
- ribavirin, Locteron™ (controlled-release interferon alpha 2b), PEG-Intron™
- Where
- 24 sites in United States, Bulgaria and 2 more
- Volunteers
- 116 people
- Sponsor
- Biolex Therapeutics, Inc.
Hepatitis C, Chronic, Liver Cirrhosis
Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)
The objective is to evaluate the efficacy and safety of combination therapy with peginterferon alfa-2b 1.0 µg/kg/week subcutaneous (SC) + ribavirin administered for 48 weeks in participants with chronic hepatitis C and type C…
- Trial name
- NCT00687219
- Testing
- Peginterferon alfa-2b, Ribavirin
- Volunteers
- 102 people
- Sponsor
- Merck Sharp & Dohme LLC
Neoplasm Metastasis
Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden
The purpose of this study is to determine the safety and tolerability of OXi4503 in subjects with relapsed or refractory carcinomas with hepatic tumor burden.
- Trial name
- OXi4503 (NCT00960557)
- Testing
- Combretastatin A1 Diphosphate (OXi4503)
- Where
- 4 sites in Australia
- Volunteers
- 16 people
- Sponsor
- Mateon Therapeutics
Hepatitis B, Chronic
Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB).
AB-10-8003 is a randomized, multi-center phase II study to evaluate the efficacy and safety of AHB-137 in subjects with HBeAg-negative CHB under stable NA treatment.
- Trial name
- NCT06550128
- Testing
- AHB-137 (24 weeks), AHB-137 (16 weeks)
- Where
- 6 sites in China
- Volunteers
- 86 people
- Sponsor
- Ausper Biopharma Co., Ltd.
Chronic Hepatitis C
A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment
Debio 025 (alisporivir) is an oral cyclophilin inhibitor with a new mechanism of action demonstrating potent anti-hepatitis C virus (HCV) activity in pre-clinical models and patients.
- Trial name
- NCT00537407
- Testing
- Debio 025, Peg-IFNα2a, Ribavirin
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Debiopharm International SA
Non Alcholic Fatty Liver Disease
Efficacy and Safety of Picroliv in Patients With Non-Alcoholic Fatty Liver Disease
This is a Phase III, multicentre, randomized, double-blind, placebo-controlled, interventional study designed to evaluate the efficacy and safety of a standardized fraction of Picrorhiza kurroa Royal Ex Benth (Picroliv®) in…
- Trial name
- NCT07452744
- Testing
- Picroliv
- Where
- 6 sites in India
- Volunteers
- 170 people
- Sponsor
- Bioagile Therapeutics Pvt. Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.